Coagulation Factor VII, Dietary Fat and Blood Lipids: A Review

Mennen, Louise; Schouten, E.G.; Grobbee, D. E.; Kluft, C.

doi:10.1055/s-0038-1650609

Cited by 64 publications

(32 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Age, gender, BMI, insulin resistance and the use of oral contraceptives have been associated with FVII levels (Balleisen et al,1985). Dietary fats and blood lipids are important determinants of FVII levels (Miller et al,1991;Mennen et al,1996). Several studies have demonstrated that three polymorphisms of the FVII gene can directly influence the FVII levels and also modulate its response to environmental stimuli (Lane et al, 1992;Humphries et al, 1994;Hong et al, 1999) The Gln353 variant of the FVII gene has consistently been associated with lower levels of FVII in white Europeans (Humphries et al, 1994), Gujarati Indians (Lane et al, 1992), Afrocaribbean Britains (Lane et al, 1992;Temple et al, 1997) and Japanese (Kario et al, 1995).…”

Section: Fvii Gene: Fvii Ivs7 Fvii R353q and Fvii Ivs1a Polymorphismmentioning

confidence: 99%

Geographic and Ethnic Differences in the Prevalence of Thrombophilia

Salazar‐Sánchez¹

2011

Thrombophilia

View full text Add to dashboard Cite

Section: Fvii Gene: Fvii Ivs7 Fvii R353q and Fvii Ivs1a Polymorphismmentioning

confidence: 99%

Geographic and Ethnic Differences in the Prevalence of Thrombophilia

Salazar‐Sánchez¹

2011

Thrombophilia

View full text Add to dashboard Cite

“…Several studies suggested that postprandial and fasting lipoproteins are associated with plasma levels or activation state of coagulation factors, and particularly of FVII [13][14][15][16][17] that plays a key role in the initiation of the clotting cascade. 18 The present investigation was aimed at testing the existence of diurnal variations of tissue factor pathway inhibitor (TFPI) in humans.…”

mentioning

confidence: 99%

Daily and Circadian Rhythms of Tissue Factor Pathway Inhibitor and Factor VII Activity

Pinotti

Bertolucci

Portaluppi

et al. 2005

ATVB

View full text Add to dashboard Cite

Objective-Diurnal variations in levels of factor VII (FVII), FVIII, proteins C and S, antithrombin, plasminogen activator inhibitor-1, prothrombin fragment F 1ϩ2 , and D-dimers in healthy humans point to the existence of circadian rhythms of coagulation factors. We sought for temporal fluctuations of tissue factor pathway inhibitor (TFPI) activity in human and mouse plasma. Methods and Results-TFPI activity showed significant daily variations with highest levels in the morning in healthy men (ϩ11%) and in mice at the light-to-dark transition (ϩ63%), the beginning of the physically active period. Variations in FVII activity paralleled those in TFPI. In mice, the feeding schedule had a strong impact on these rhythms. Although restricted feeding and fasting shifted the peak of TFPI, the FVII peak disappeared. Investigation of temporal fluctuations in constant darkness indicated the existence of daily rhythms for TFPI and of true circadian rhythms for FVII. Conclusions-For the first time, we report, both in humans and mice, temporal variations in TFPI activity. The coherent variations in FVII and TFPI activity could interplay to maintain the coagulation equilibrium. The chronobiological patterns should be considered to analyze activity levels of these factors. Moreover, the mouse model could be exploited to investigate modifiers of coagulation rhythms potentially associated to morning peaks of cardiovascular events. Key Words: factor VII Ⅲ TFPI Ⅲ circadian Ⅲ feeding schedule Ⅲ mouse model F requencies of thromboembolic events in humans exhibit marked diurnal variations, 1-3 with peaks from morning to noon. Temporal variations in the occurrence of hemorrhagic events have also been reported. 4 Fluctuations in coagulation factor levels able to influence the hemostatic balance might contribute to these adverse outcomes. Diurnal rhythms in levels of factor VII (FVII), 5 FVIII, 6 proteins C and S 7 , antithrombin, 7 and plasminogen activator inhibitor (PAI)-1 8 have been described in healthy humans. Temporal oscillations in prothrombin fragment F 1ϩ2 5-6 and D-dimer, 6 markers of thrombin generation and fibrinolysis, have been also described. These variations could reflect the existence of circadian rhythms of blood coagulation factors. Circadian rhythms are the overt expression of an internal timing mechanism measuring daily time, with the fundamental adaptive function of providing optimal temporal organization of physiological processes in relation to the environment. 9 Because formal assessment of circadian rhythms in coagulation factor levels is hardly feasible in humans, a circadian control has been so far demonstrated in a mouse model for PAI-1 10 -11 and fibrinogen 12 mRNA expression.Among factors interacting with circadian rhythms, daily availability of food represents a major component. Several studies suggested that postprandial and fasting lipoproteins are associated with plasma levels or activation state of coagulation factors, and particularly of FVII 13-17 that plays a key role in the initiation of the clott...

show abstract

“…Instead, the activity of FVII may be regulated in response to hormones such as estrogen [94] and insulin [95] . Plasma fVII levels are also known to associate with plasma lipid concentration [96,97] . In addition to the liver, fVII may also be synthesized in monocytes and macrophages [98,99] , although the mechanisms of FVII regulation in these non-hepatocytic cells remains unknown.…”

Section: Ectopic Expression Of Fvii In Breast Cancer Cellsmentioning

confidence: 99%

Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets

Koizume

Miyagi

2014

WJCO

View full text Add to dashboard Cite

Breast cancer is a leading cause of cancer death in women, worldwide. Fortunately, breast cancer is relatively chemosensitive, with recent advances leading to the development of effective therapeutic strategies, significantly increasing disease cure rate. However, disease recurrence and treatment of cases lacking therapeutic molecular targets, such as epidermal growth factor receptor 2 and hormone receptors, referred to as triple-negative breast cancers, still pose major hurdles in the treatment of breast cancer. Thus, novel therapeutic approaches to treat aggressive breast cancers are essential. Blood coagulation factor VII (fVII) is produced in the liver and secreted into the blood stream. Tissue factor (TF), the cellular receptor for fVII, is an integral membrane protein that plays key roles in the extrinsic coagulation cascade. TF is overexpressed in breast cancer tissues. The TF-fVII complex may be formed in the absence of injury, because fVII potentially exists in the tissue fluid within cancer tissues. The active form of this complex (TF-fVIIa) may stimulate the expression of numerous malignant phenotypes in breast cancer cells. Thus, the TF-fVII pathway is a potentially attractive target for breast cancer treatment. To date, a number of studies investigating the mechanisms by which TF-fVII signaling contributes to breast cancer progression, have been conducted. In this review, we summarize the mechanisms controlling TF and fVII synthesis and regulation in breast cancer cells. Our current understanding of the TF-fVII pathway as a mediator of breast cancer progression will be also described. Finally, we will discuss how this knowledge can be applied to the design of future therapeutic strategies. Key words: Breast cancer; Blood coagulation; Tissue factor; Coagulation factor VII; Gene regulation; Therapeutic strategy Core tip: Breast cancer is a worldwide problem. Difficulties with treating the disease and its recurrence persist due, in part, to a lack of therapeutic molecular targets. Blood coagulation factor VII (fVII) is generally produced in the liver. Tissue factor (TF), the cellular receptor for fVII, is an integral membrane protein that plays key roles in the extrinsic coagulation cascade. Formation of the TF-fVII complex causes contributes to the malignant phenotype of breast cancer cells. In this review, we summarize the breast cancer biology associated with the TF-fVII pathway. Further, we will discuss how these mechanisms can be targeted as therapeutics for this aggressive disease.Koizume S, Miyagi Y. Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.

show abstract

Coagulation Factor VII, Dietary Fat and Blood Lipids: A Review

Cited by 64 publications

References 42 publications

Geographic and Ethnic Differences in the Prevalence of Thrombophilia

Geographic and Ethnic Differences in the Prevalence of Thrombophilia

Daily and Circadian Rhythms of Tissue Factor Pathway Inhibitor and Factor VII Activity

Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets

Contact Info

Product

Resources

About